Johns Hopkins HIV Guide
Elvitegravir
INDICATIONS
FDA
FDA
- Treatment of HIV-infection as part of a single tablet regimen (e.g., Stribild, Genvoya) for adults who are ART-naive or to replace a stable regimen in patients who are virologically suppressed
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HIV-infection for adults who are ARV-experienced but not virologically suppressed on a stable regimen
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 3, 2016
Citation
Pham, Paul A, and Alice J Hsu. "Elvitegravir." Johns Hopkins HIV Guide, 2016. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/5.3/Elvitegravir.
Pham PA, Hsu AJ. Elvitegravir. Johns Hopkins HIV Guide. 2016. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/5.3/Elvitegravir. Accessed June 3, 2023.
Pham, P. A., & Hsu, A. J. (2016). Elvitegravir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/5.3/Elvitegravir
Pham PA, Hsu AJ. Elvitegravir [Internet]. In: Johns Hopkins HIV Guide. ; 2016. [cited 2023 June 03]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/5.3/Elvitegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Elvitegravir
ID - 545235
A1 - Pham,Paul,Pharm.D. BCPS
AU - Hsu,Alice,Pharm.D.
Y1 - 2016/11/03/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545235/5.3/Elvitegravir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
